Sonocrystallization is the process of using ultrasound to effect controlled nucleation in crystallization processes, allowing the precise and consistent production of high purity particles of a defined shape and size.
Prosonitron®Prosonitron® is the unique patented reactor technology developed by Prosonix to deliver power ultrasound into a chemical process in a controlled way. Particle size, shape, morphology and surface characteristics can be exquisitely controlled using Prosonitron® and it is the core technology underpinning DISCUS®, UMAX®, SAX™ and MCP™ technologies. Prosonitron®is already being used by multiple partners on a commercial scale and is validated across scale in cGMP environments.
DISCUS®DISCUS® is a novel process intensified particle engineering technique based on ultrasound-mediated solvent/anti-solvent crystallisation. DISCUS®has been developed by Prosonix to facilitate formation of submicron to micron-sized particles directly from solution thereby eliminating the need for jet milling. It is particularly useful in preparing API for pMDI formulation preparations.
UMAX®UMAX®particle engineering technology facilitates the manufacture of spheroidal drug particles with high surface rugosity. This property is important for minimising particle-to-particle cohesivity and particle-to-carrier adhesivity, thus maximising performance in DPI.
Multi-component Particle™ (MCP™) Technology
MCP™ technology allows the combination of multiple APIs in a pre-determined and constant ratio in each and every particle of the product. Multi-component particles are fully co-associated and have been shown to facilitate co-localisation of API at the site of action throughout the lung which in turn offers the potential for enhanced localised synergistic pharmacological effect, dose sparing and compliance, at reduced cost and via simple inhaler devices.
Prosonix has successfully combined APIs within single particles in pre-determined ratios between 1:1 and 1:100 and established the technology's potential to ensure enhanced co-association and co-localisation of drug combinations at the target site. MCP™ has also been shown to virtually eliminate the variability associated with blending of two or more micronized powders, and overcoming the innate chemistry and regulatory challenges of bi-functional MABA (muscarinic antagonist- β2-agonist) molecules.
Prosonix has created MCPs™ of many leading marketed respiratory combinations, including combinations of ICS/LABA, ICS/LAMA and ICS/LABA/LAMA.
SAX™ particle engineering technology enables the production of microcrystalline particles with narrow size distribution and is fundamental to the preparation of particulate pharmaceuticals with defined physicochemical properties. SAX™ involves atomising a solution containing one or more API, conditioning the droplets formed, capturing the droplets in a benign solution and then applying ultrasound to affect controlled sonocrystallization within each droplet, delivering microcrystalline API material having significant performance enhancing benefits. The crystalline particles are then created using spray-drying or supercritical carbon dioxide drying.